101 related articles for article (PubMed ID: 7505977)
1. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.
Oesterling JE; Suman VJ; Zincke H; Bostwick DG
Urol Clin North Am; 1993 Nov; 20(4):687-93. PubMed ID: 7505977
[TBL] [Abstract][Full Text] [Related]
2. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
3. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
Park HK; Hong SK; Byun SS; Lee SE
Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
[TBL] [Abstract][Full Text] [Related]
4. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer.
Elgamal AA; Cornillie FJ; Van Poppel HP; Van de Voorde WM; McCabe R; Baert LV
J Urol; 1996 Sep; 156(3):1042-7; discussion 1047-9. PubMed ID: 8709304
[TBL] [Abstract][Full Text] [Related]
5. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Presti JC; Hovey R; Carroll PR; Shinohara K
J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
[TBL] [Abstract][Full Text] [Related]
7. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
8. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Geary ES; Stamey TA
J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
11. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Fowler JE; Bigler SA; Miles D; Yalkut DA
J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
13. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).
Vis AN; Hoedemaeker RF; Roobol M; van der Kwast TH; Schröder FH
Prostate; 2001 Jun; 47(4):252-61. PubMed ID: 11398172
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Lerner SE; Seay TM; Blute ML; Bergstralh EJ; Barrett D; Zincke H
J Urol; 1996 Mar; 155(3):821-6. PubMed ID: 8583584
[TBL] [Abstract][Full Text] [Related]
16. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
Labrie F; Candas B; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M
Urology; 1996 Feb; 47(2):212-7. PubMed ID: 8607237
[TBL] [Abstract][Full Text] [Related]
18. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
Gosselaar C; Roobol MJ; Roemeling S; van der Kwast TH; Schröder FH
Prostate; 2007 Feb; 67(2):154-61. PubMed ID: 17044079
[TBL] [Abstract][Full Text] [Related]
19. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
Hammerer P; Huland H
Urologe A; 1995 Jul; 34(4):283-9. PubMed ID: 7545842
[TBL] [Abstract][Full Text] [Related]
20. Identification of clinically significant prostate cancer by prostate-specific antigen screening.
Smith RP; Malkowicz SB; Whittington R; VanArsdalen K; Tochner Z; Wein AJ
Arch Intern Med; 2004 Jun; 164(11):1227-30. PubMed ID: 15197049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
